Doeren Mayhew expands into Atlanta with AGL CPA Group merger
AGL CPA Group, which now operates under the Doeren Mayhew brand, serves a diverse clientele that includes closely held businesses and high-net-worth individuals, providing consulting, tax and attestation services.
The merger brings more than 20 employees from AGL into Doeren Mayhew.
Jay Robbins has been appointed as managing principal for the region, with AGL partners Bradley Sienkiewicz, Jim Leutenegger, Justin Bailey and Daniel Cassandra joining the company's leadership team as principals.
Doeren Mayhew CEO Chad Anschuetz said: 'Finding the right strategic partner in the Atlanta community was an important part of our vision for growth in the south-east.
'AGL's established presence of reputable work and technical expertise will accelerate our growth trajectory in this pivotal international hub.
'We are excited to welcome the AGL team to the Doeren Mayhew family, and we look forward to serving the local community with them by our side.'
This transaction establishes Doeren Mayhew's presence in Atlanta with a new office in Duluth and enhances its capabilities across several practice areas including audit, CFO advisory, construction, manufacturing, professional services, real estate, tax and transaction advisory.
The practice aims to leverage AGL's expertise in technology, broker-dealer and alternative investments to broaden its industry reach.
This merger represents Doeren Mayhew's sixth addition in 2025, following its expansion into Nashville through the acquisition of Thurman Campbell Group in March.
AGL co-founder and managing partner Bradley Sienkiewicz said: 'We are thrilled to join Doeren Mayhew. Culture was the most important factor in finding a partner to grow alongside.
'Doeren Mayhew shares a common culture of excellence, great people and bullish vision for the future. Combining forces seems like a natural progression for AGL.
'It gives us the dynamic platform to provide expansive resources and solutions to our clients, while providing unparalleled career opportunities to our team.'
Alan Koltin, CEO of Koltin Consulting Group, who advised both firms on the combination said: 'Expanding into the Atlanta market was a high priority for Doeren Mayhew, and they found the perfect firm in AGL! AGL is young, entrepreneurial and has a great reputation in the technology space.
"Doeren Mayhew has had significant success in executing on its M&A and lateral talent strategies.'
"Doeren Mayhew expands into Atlanta with AGL CPA Group merger" was originally created and published by International Accounting Bulletin, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Pharma CEOs downplay impact of tariffs amid rising cost concerns
Despite analyst warnings of heightened financial risk, pharma CEOs across the US and Europe remain confident that the latest US-EU trade deal and associated tariffs will have limited impact. As per a new deal between the two global economic powerhouses, the EU will pay the US a tariff rate of 15% for pharmaceuticals. Medicines are the largest European exports to the US by value, and the EU accounts for approximately 60% of all pharmaceutical imports to the US. Top-selling drugs such as AbbVie's Humira (adalimumab), MSD's Keytruda (pembrolizumab), and Novo Nordisk's Ozempic (semaglutide), for example, are manufactured in Europe and sent to the US, representing billion-dollar markets. Analysts from GlobalData's Pharma Strategic Intelligence team say that: 'Companies manufacturing pharmaceutical products in Europe will need to anticipate financial exposure when planning launches in the US due to the unfavourable gross to net dynamics, weakened pricing leverage with US payers, and slower commercial uptake as insurers reassess cost effectiveness due to the tariffs.' US President Donald Trump has had a sharp focus on the pharma industry since assuming office. Analysts predict that adding duties to incoming goods will likely elevate costs across the pharmaceutical value chain, ultimately raising drug prices for patients. The policies make for interesting analysis when combined with his desire to cut prescription prices in the country. Diederik Stadig, sector economist for TMT & healthcare at ING, wrote in a July note: 'A tariff would hurt consumers most of all, as they would feel the inflationary effect of tariffs directly when paying for prescriptions.' The European Federation of Pharmaceutical Industries and Associations (EFPIA), for example, has maintained that tariffs on medicines are ineffective. The group says such policies only hinder patient access to medicines. GlobalData also forecasts disruptions to launch planning, particularly late-stage assets with EU-based manufacturing and production planned for entry into the US. R&D budgets of pharmaceutical companies are already under pressure and the firefighting of tariffs could place additional strain on resources. CEOs signal resilience CEOs of big pharma companies, however, are maintaining a brave face despite the projected headwinds. The UK-EU trade deal announcement arrived in the middle of the pharma industry's Q2 reporting period, where execs were pressed on financial outlooks. In a Q2 earnings call, AbbVie's CEO Rob Michael said the US company is 'fairly insulated' from any tariff-related impacts in 2025, though caveated that the company would not speculate on the longer-term consequences. AstraZeneca shared the same sentiment. CEO Pascal Soriot said the British-Swedish drugmaker is 'almost self-sufficient in terms of supply,' adding that 'tariffs is not an issue that is really affecting us very much.' However, AstraZeneca is on a long list of pharma companies transferring manufacturing to the US. This includes a $4bn investment to build a new manufacturing plant in Virginia. Sanofi has outlaid $20bn to bolster US manufacturing through 2030 and Roche unveiled a similar $50bn investment strategy, to name just a couple. The team at GlobalData added: 'Ultimately, the recent US-EU trade deal has increased the level of uncertainty within the pharmaceutical industry, raising concerns on the potential of tariffs increasing past 15% in the future. 'While the full impact will take time to unfold, it will be interesting to see the adoption of different strategies on how the pharmaceutical industry looks to balance innovation, and ensuring patient access, while managing the pressures of tariffs as they unfold into a certain reality.' A critical part of the industry's future also relies on the outcome of the US government's Section 232 investigation into the drug sector. The probe, which Trump initiated to evaluate the role of medicine imports on national security, could result in further tariffs being imposed. MSD CEO Rob Davis said in the company's Q2 earnings call: 'We need to see more clarity both from the administration and just overall as to how exactly [the 15% tariff] is going to play out. It's still not clear exactly how this relates relative to the February investigation and the timing of whether these apply now or will be phased in until there's further guidance.' AbbVie's Michael said: 'We're having constructive discussions with the administration on sectoral tariffs. Clearly, the best way to motivate that is through tax incentives as well as a trade agenda that prioritises innovation. We're well positioned as a company, but we're not going to be able to really give you any details until we understand the outcome of the 232 investigation.' Navigate the shifting tariff landscape with real-time data and market-leading analysis. Request a free demo for GlobalData's Strategic Intelligence . "Pharma CEOs downplay impact of tariffs amid rising cost concerns" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
7 minutes ago
- Yahoo
The jobs data revisions that cost a US government statistician her job
(Reuters) -The revisions to previous estimates of the size of U.S. payrolls gains for May and June that prompted President Donald Trump to fire Bureau of Labor Statistics Commissioner Erika McEntarfer on Friday were by any measure extraordinarily large. Indeed, the combined downward revision for the two months of 258,000 was the largest - outside of those during the early months of the COVID-19 pandemic - since at least 1979. Here's a quick graphical breakdown: FIRST REVISION The monthly nonfarm payrolls report, released typically on the first Friday of each month, includes an initial estimate of employment changes for the immediately preceding month and revisions to the earlier estimates for the prior two months. BLS makes the revisions because more survey responses come in over the ensuing weeks and because it updates the seasonal factors affecting each month's estimates. The BLS on Friday said 133,000 fewer jobs had been created in June than first estimated. Over the last several years, the first estimate of the net change in payrolls each month has been revised lower more often than not. It has been revised down in eight of the last 12 BLS reports over the last year. The downward revision on Friday was the largest since the first estimate of payrolls gains for March 2021, published in April 2021, was revised down by 146,000 a month later. Over the last three years through June, the median estimate revision was -10,000. That contrasts with a median increase of 8,000 during the decade before the pandemic and a median increase of 2,000 over the series history since 1979. SECOND REVISION The total for May's payroll gains was revised lower by 125,000 in Friday's report, when the third estimate for payrolls for that month was published. That figure was the largest downward reduction of payrolls gains for a second revision - outside of the pandemic era - since the estimate for March 1983 was revised down by 127,000 in the report published in June 1983. COMBINED REVISION The combined downward revision for the two previous months - May and June - was larger than anything reported outside of the pandemic era. Indeed, the estimates for the two prior months combined have more often than not been revised higher. Since 1979, the median two-month combined estimate change was an upward revision of 10,000. Measured in absolute terms - revisions in either direction - Friday's revision also stands out. There have only been four larger revisions: +709,000 for November and December 2021; -642,000 for March and April 2020; +285,000 for August and September 1983; and +414,000 for April and May 1981. Solve the daily Crossword
Newsweek
9 minutes ago
- Newsweek
Multiple Kentucky Whiskey Distilleries File for Bankruptcy
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Kentucky's storied whiskey business is facing significant difficulties, with a number of distilleries filing for bankruptcy amid mounting debt, falling demand and uncertain global trade conditions. Last month, LMD Holdings, the parent company of the Danville-based Luca Mariano Distillery, filed for Chapter 11 bankruptcy in the Eastern District of Michigan, where it is registered. Newsweek has contacted the company via email for comment. Why It Matters The state's bourbon and whiskey industry—estimated to be worth about $9 billion, according to the Kentucky Distillers' Association—is currently facing an array of challenges. Many, including cost-pressured consumers, shifting preferences among young drinkers away from whiskey and potential ramifications of tariffs on sales in key export markets, are also impacting the nationwide spirits industry and the thousands it employs nationwide. Bottles of whiskey on a shelf at a store on March, 15, 2025. Bottles of whiskey on a shelf at a store on March, 15, 2025. Peter Kneffel/picture-alliance/dpa/AP Images What To Know Court filings show that LMD Holdings is burdened with a significant amount of debt, including a "likely claim of over $25,000,000" owed to its largest creditor. Some of the claims are under dispute, according to the Lexington Herald-Leader. Owner Francesco Viola told the paper that the bankruptcy filing, which came only weeks after the distillery's June launch, was intended to "maximize the value of the assets for all stakeholders," and that the company was "poised to emerge successfully, ideally with the support of its employees, customers, community and creditors." The filing follows similar reports of other Kentucky distilleries facing financial difficulties. Garrard County Distilling, a $250 million independent distillery that began production in early 2024, has been placed in receivership and closed in April amid a failure to settle unpaid debts. Late last year, Stoli Group USA filed for bankruptcy along with its affiliate, the Kentucky Owl whiskey brand. That followed a sustained slowdown in spirits demand in the U.S., according to CNN, as well as a cyberattack that took down the majority of its operations. More recently, sales of the Kentucky bourbon Wild Turkey have slumped. In its half-year results, Campari Group, which owns the brand and its Lawrenceburg and Danville distilleries, reported that sales of Wild Turkey & Russell's Reserve had fallen 8.1 percent year-over-year "due to a soft trend for Wild Turkey in its core United States market." Beyond bankruptcies and financial difficulties, the American spirits and wine industry has also seen a number of companies cut jobs in an effort to stay profitable in an increasingly uncertain trading environment. In January, Jack Daniel's parent company, Brown-Forman, announced it would be eliminating about 12 percent of its workforce and closing a barrel-making plant in Louisville, Kentucky. What People Are Saying Luca Mariano Distillery owner Francesco Viola, in a statement to the Lexington Herald-Leader: "We filed to maximize the value of the assets for all stakeholders. Luca Mariano Distillery and LMD Holdings have a successful business model, have weathered the prior economic challenges in our industry, and are poised to emerge successfully, ideally with the support of its employees, customers, community and creditors."
